
|Articles|April 26, 2004
Real-world VISION trial demonstrates safety and efficacy of anti-VEGF in all AMD subtypes
One-year data from the pivotal Phase II/III VEGF Inhibition Study inOcular Neovascularization (VISION) indicate that selective anti-VEGF165(Macugen, Eyetech/Pfizer) treatment improves visual outcomes and offersa highly favorable systemic and ocular safety profile, said Steven Schwartz,MD.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
3
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
4
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis
5



























